Researchers uncovered a combination drug therapy that yielded promising results against myelodysplastic syndrome ...

Introduction: DNA methylation inhibitors (azacitidine, decitabine) have revolutionized the treatment dilemma of myelodysplastic syndromes (MDS), a group of malignant hematopoietic disorders. This ...

The first indication AB8939 is being developed for is acute myeloid leukemia (AML). Cytarabine (Ara-C) and azacytidine are standard chemotherapies for AML treatment, however, drug resistance is a ...

Treatment with the hypomethylating agent 5-azacytidine (AZA) increases survival in high-risk (HR) myelodysplastic syndrome (MDS) patients, but predicting patient response and overall survival remains ...

1. Kröger N, Sockel K, Wolschke C, et al. Comparison between 5-azacytidine treatment and allogeneic stem-cell transplantation in elderly patients with advanced MDS according to donor availability ...

The development of large and increasingly complex proteins is ushering in a new era of advanced biotherapeutics, and engineered mammalian cell lines have emerged as the preferred system for ...

The patient was treated with intravenous azacitidine at a dose of 32 mg/m2 for 4 days, every 4 weeks. Researchers from France presented the case of a patient with early T-cell precursor acute ...

The researchers discovered that combining venetoclax with a drug called 5-azacytidine significantly increased its effectiveness across many MM cell lines, indicating a broader potential patient ...